NEW YORK, October 5, 2017 /PRNewswire/ --
If you want a Stock Review on IMGN, INCY, INFI, or INSM then come overto http://dailystocktracker.com/register/ and sign up for your free customized report. On Wednesday, October 04, 2017, the NASDAQ Composite ended the trading session at 6,534.63, up 0.04%; the Dow Jones Industrial Average
Waltham, Massachusetts headquartered ImmunoGen Inc.'s stock finished Wednesday's session 2.35% higher at $7.83 with a total trading volume of 2.03 million shares. The Company's shares have advanced 202.32% over the past twelve months and 283.82% since the start of this year. The stock is trading above its 50-day and 200-day moving averages by 17.51% and 70.19%, respectively. Additionally, shares of ImmunoGen, which develops targeted anticancer therapeutics, have a Relative Strength Index (RSI) of 63.30. Sign up and read the free research report on IMGN at:
On Wednesday, shares in Wilmington, Delaware headquartered Incyte Corp. recorded a trading volume of 1.34 million shares. The stock ended the session 0.91% higher at $113.83. The Company's shares have advanced 20.88% over the last twelve months and 13.52% on an YTD basis. The stock is trading below its 50-day moving average by 8.58%. Moreover, shares of Incyte, which focuses on the discovery, development, and commercialization of proprietary therapeutics in oncology in the US and internationally, have an RSI of 39.27.
On September 15th, 2017, research firm RBC Capital Markets initiated a 'Sector Perform' rating on the Company's stock, with a target price of $136 per share. The complimentary research report on INCY can be downloaded at:
Cambridge, Massachusetts headquartered Infinity Pharmaceuticals Inc.'s shares closed the day 7.38% higher at $1.31. The stock recorded a trading volume of 2.05 million shares, which was above its three months average volume of 826.66 thousand shares. The Company's shares have gained 5.65% in the last month. The stock is trading above its 50-day moving average by 10.90%. Additionally, shares of Infinity Pharma, which develops medicines for patients with difficult-to-treat diseases in the US, have an RSI of 56.68. Register for free on DailyStockTracker.com and access the latest report on INFI at:
Shares in Bridgewater, New Jersey headquartered Insmed Inc. finished 0.51% higher at $31.24. The stock recorded a trading volume of 443,033 shares. The Company's shares have advanced 15.75% in the last month, 77.20% in the previous three months, 114.56% over the last twelve months, and 136.13% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 55.32% and 82.16%, respectively. Furthermore, shares of Insmed, which focuses on the development and commercialization of therapies for patients with rare diseases, have an RSI of 72.52.
On September 05th, 2017, research firm Evercore ISI reiterated its 'Outperform' rating on the Company's stock with an increase of the target price from $28 a share to $40 a share. Get free access to your research report on INSM at:
Daily Stock Tracker:
Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
DST has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org . Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by DST. DST is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
DST, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. DST, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, DST, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither DST nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: email@example.com Phone number: (207)331-3313 Office Address: 377 Rivonia Boulevard, Rivonia, South Africa
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
Subscribe to our Free Newsletters!
Fallopian tube cancer is a form of gynecologic cancer arising in the fallopian tubes, which are ...
Cushing syndrome is a collection of symptoms caused due to excessive amount of cortisol in the body ...
CAR T-cell therapy is a type of gene therapy where the patient's T-lymphocytes are genetically ...View All